Domain Antibodies | List of Frontiers open access articles

Review

Published on 17 May 2024

Single domain antibodies from camelids in the treatment of microbial infections

in Vaccines and Molecular Therapeutics

Henri De Greve
Antonella Fioravanti

Frontiers in Immunology

doi 10.3389/fimmu.2024.1334829

8,647 views
2 citations

Original Research

Published on 04 Apr 2022

Discovery of Anti-PD-L1 Human Domain Antibodies for Cancer Immunotherapy

in Cancer Immunity and Immunotherapy

Hao Liu
Yanli Liu
Zhen Zhao
Yuanke Li
Bahaa Mustafa
Zhijin Chen
Ashutosh Barve
Akshay Jain
Xiaolan Yao
Guangfu Li

Frontiers in Immunology

doi 10.3389/fimmu.2022.838966

9,129 views
13 citations

Original Research

Published on 01 Apr 2022

Engineering the Single Domain Antibodies Targeting Receptor Binding Motifs Within the Domain III of West Nile Virus Envelope Glycoprotein

in Virology

Jana Hruškovicová
Katarína Bhide
Patrícia Petroušková
Zuzana Tkáčová
Evelína Mochnáčová
Ján Čurlík
Mangesh Bhide
Amod Kulkarni

Frontiers in Microbiology

doi 10.3389/fmicb.2022.801466

9,426 views
15 citations

Original Research

Published on 23 Dec 2020

Single Domain Antibodies Targeting Receptor Binding Pockets of NadA Restrain Adhesion of Neisseria meningitidis to Human Brain Microvascular Endothelial Cells

in Molecular Diagnostics and Therapeutics

Amod Kulkarni
Evelína Mochnáčová
Petra Majerova
Ján Čurlík
Katarína Bhide
Patrícia Mertinková
Mangesh Bhide

Frontiers in Molecular Biosciences

doi 10.3389/fmolb.2020.573281

5,711 views
14 citations

Original Research

Published on 14 Jun 2017

Fungal Glucosylceramide-Specific Camelid Single Domain Antibodies Are Characterized by Broad Spectrum Antifungal Activity

in Antimicrobials, Resistance and Chemotherapy

Barbara De Coninck
Peter Verheesen
Christine M. Vos
Inge Van Daele
Miguel F. De Bolle
Joao V. Vieira
Marnix Peferoen
Bruno P. A. Cammue
Karin Thevissen

Frontiers in Microbiology

doi 10.3389/fmicb.2017.01059

8,403 views
13 citations

Original Research

Published on 15 Aug 2025

Targeting the major pro-inflammatory interleukin-6-type cytokine receptor gp130 by antagonistic single domain antibodies

in Cytokines and Soluble Mediators in Immunity

Silke Pudewell
Julia Heuser
Inna Dorogobed
Britta Lipinski
Thi Hong Hue Tran
Pia Metzenmacher
Richard Kunze
Felix Geyer
Stefan Zielonka
Doreen M. Floss

Frontiers in Immunology

doi 10.3389/fimmu.2025.1613004

4,569 views
1 citation

Brief Research Report

Published on 09 Oct 2023

Human antibody VH domains targeting uPAR as candidate therapeutics for cancers

in Cancer Immunity and Immunotherapy

Xiaojie Chu
Wei Li
Margaret G. Hines
Ilya Lyakhov
John W. Mellors
Dimiter S. Dimitrov

Frontiers in Oncology

doi 10.3389/fonc.2023.1194972

3,999 views
6 citations

Perspective

Published on 21 Oct 2014

Nanobodies as modulators of inflammation: potential applications for acute brain injury

in Cellular Neuropathology

Björn Rissiek
Friedrich Koch-Nolte
Tim Magnus

Frontiers in Cellular Neuroscience

doi 10.3389/fncel.2014.00344

20,546 views
44 citations

Perspective

Published on 22 Oct 2020

Perspective: Reducing SARS-CoV2 Infectivity and Its Associated Immunopathology

in Viral Immunology

Abhishek Dubey
Surbhi Dahiya
Barry T. Rouse
Sharvan Sehrawat

Frontiers in Immunology

doi 10.3389/fimmu.2020.581076

4,888 views
7 citations

Brief Research Report

Published on 23 Dec 2022

Plant production of high affinity nanobodies that block SARS-CoV-2 spike protein binding with its receptor, human angiotensin converting enzyme

in Synthetic Biology

Marco Pitino
Laura A. Fleites
Lauren Shrum
Michelle Heck
Robert G. Shatters

Frontiers in Bioengineering and Biotechnology

doi 10.3389/fbioe.2022.1045337

4,451 views
4 citations

Original Research

Published on 28 Sep 2023

AI/ML combined with next-generation sequencing of VHH immune repertoires enables the rapid identification of de novo humanized and sequence-optimized single domain antibodies: a prospective case study

in Biological Modeling and Simulation

Paul Arras
Han Byul Yoo
Lukas Pekar
Thomas Clarke
Lukas Friedrich
Christian Schröter
Jennifer Schanz
Jason Tonillo
Vanessa Siegmund
Achim Doerner

Frontiers in Molecular Biosciences

doi 10.3389/fmolb.2023.1249247

18,166 views
24 citations

Brief Research Report

Published on 13 Aug 2024

A single domain antibody-based Luminex assay for the detection of SARS-CoV-2 in clinical samples

in Vaccines and Molecular Therapeutics

Ellen R. Goldman
Victor A. Sugiharto
Lisa C. Shriver-Lake
Andrew M. Garcia
Shuenn-Jue Wu
Sarah A. Jenkins
Hua-Wei Chen

Frontiers in Immunology

doi 10.3389/fimmu.2024.1446095

2,992 views
2 citations

Review

Published on 11 Sep 2023

Unleashing the power of shark variable single domains (VNARs): broadly neutralizing tools for combating SARS-CoV-2

in Vaccines and Molecular Therapeutics

Olivia Cabanillas-Bernal
Blanca J. Valdovinos-Navarro
Karla E. Cervantes-Luevano
Noemi Sanchez-Campos
Alexei F. Licea-Navarro

Frontiers in Immunology

doi 10.3389/fimmu.2023.1257042

5,279 views
4 citations

Original Research

Published on 06 Jul 2023

Identification and characterisation of anti-IL-13 inhibitory single domain antibodies provides new insights into receptor selectivity and attractive opportunities for drug discovery

in Cytokines and Soluble Mediators in Immunity

Kayleigh Walker
Roberta Baravalle
Rachel Holyfield
Jacqueline Kalms
Helena Wright
Chitra Seewooruthun
Frederick W. Muskett
Anthony Scott-Tucker
Andy Merritt
Alistair Henry

Frontiers in Immunology

doi 10.3389/fimmu.2023.1216967

6,523 views
3 citations

Original Research

Published on 19 Apr 2024

Scrutiny of chimeric antigen receptor activation by the extracellular domain: experience with single domain antibodies targeting multiple myeloma cells highlights the need for case-by-case optimization

in Cancer Immunity and Immunotherapy

Heleen Hanssens
Fien Meeus
Yannick De Vlaeminck
Quentin Lecocq
Janik Puttemans
Pieterjan Debie
Timo W. M. De Groof
Cleo Goyvaerts
Kim De Veirman
Karine Breckpot

Frontiers in Immunology

doi 10.3389/fimmu.2024.1389018

5,900 views
5 citations

Mini Review

Published on 09 Jun 2017

Camelid Single-Domain Antibodies As an Alternative to Overcome Challenges Related to the Prevention, Detection, and Control of Neglected Tropical Diseases

in Vaccines and Molecular Therapeutics

Carla F. C. Fernandes
Soraya dos S. Pereira
Marcos B. Luiz
Juliana P. Zuliani
Gilvan P. Furtado
Rodrigo G. Stabeli

Frontiers in Immunology

doi 10.3389/fimmu.2017.00653

18,832 views
42 citations

Articles

Single domain antibodies from camelids in the treatment of microbial infections

Discovery of Anti-PD-L1 Human Domain Antibodies for Cancer Immunotherapy

Engineering the Single Domain Antibodies Targeting Receptor Binding Motifs Within the Domain III of West Nile Virus Envelope Glycoprotein

Single Domain Antibodies Targeting Receptor Binding Pockets of NadA Restrain Adhesion of Neisseria meningitidis to Human Brain Microvascular Endothelial Cells

Fungal Glucosylceramide-Specific Camelid Single Domain Antibodies Are Characterized by Broad Spectrum Antifungal Activity

Targeting the major pro-inflammatory interleukin-6-type cytokine receptor gp130 by antagonistic single domain antibodies

Human antibody VH domains targeting uPAR as candidate therapeutics for cancers

Nanobodies as modulators of inflammation: potential applications for acute brain injury

Perspective: Reducing SARS-CoV2 Infectivity and Its Associated Immunopathology

Plant production of high affinity nanobodies that block SARS-CoV-2 spike protein binding with its receptor, human angiotensin converting enzyme

AI/ML combined with next-generation sequencing of VHH immune repertoires enables the rapid identification of de novo humanized and sequence-optimized single domain antibodies: a prospective case study

A single domain antibody-based Luminex assay for the detection of SARS-CoV-2 in clinical samples

Unleashing the power of shark variable single domains (VNARs): broadly neutralizing tools for combating SARS-CoV-2

Identification and characterisation of anti-IL-13 inhibitory single domain antibodies provides new insights into receptor selectivity and attractive opportunities for drug discovery

Scrutiny of chimeric antigen receptor activation by the extracellular domain: experience with single domain antibodies targeting multiple myeloma cells highlights the need for case-by-case optimization

Camelid Single-Domain Antibodies As an Alternative to Overcome Challenges Related to the Prevention, Detection, and Control of Neglected Tropical Diseases